Guangmeng Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Guangmeng Xu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Haina Zhang
Department of Rehabilitation, The Second Hospital of Jilin University, Jilin University, Changchun, 130000, PR China
2 shared publicationsLinxian Zhao
Department of General Surgery, The Second Hospital of Jilin University, Jilin University, Changchun, 130000, PR China
2 shared publications- Hongmei Dong
Department of Gastrointestinal Surgery, The Second Hospital of Jilin University, Changchun, China
1 shared publication Jiaming Cui
Changchun University of Chinese Medicine, Jilin University, Changchun, 130000, PR China
1 shared publicationJiang Jun-Jie
Department of Rehabilitation, The Second Hospital of Jilin University, Changchun 130000, PR China
1 shared publication- Jingru Ma
Department of Laboratory Medicine, The Second Hospital of Jilin University, Changchun, China
1 shared publication
Latest Publications
- Open Access
- 1 June 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 176, 116830
Peptides derived from growth factors: Exploring their diverse impact from antimicrobial properties to neuroprotection
- 1 June 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 176, 116830
Open AccessPeptides derived from growth factors: Exploring their diverse impact from antimicrobial properties to neuroprotection
- 23 February 2024
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 186, 114544
Isoliquiritin counteracts cadmium-induced intestinal damage in mice through enhancing intestinal barrier function and inhibiting apoptosis
- 23 February 2024
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 186, 114544
Isoliquiritin counteracts cadmium-induced intestinal damage in mice through enhancing intestinal barrier function and inhibiting apoptosis
- Open Access
- 20 September 2021
- Published by Springer Nature in Discover Oncology
- Vol. 12 (1) , 1-19
Interaction of microRNAs with sphingosine kinases, sphingosine-1 phosphate, and sphingosine-1 phosphate receptors in cancer
Sphingosine-1-phosphate (S1P), a pleiotropic lipid mediator, participates in various cellular processes during tumorigenesis, including cell proliferation, survival, drug resistance, metastasis, and angiogenesis. S1P is formed by two sphingosine kinases (SphKs), SphK1 and SphK2. The intracellularly produced S1P is delivered to the extracellular space by ATP-binding cassette (ABC) transporters and spinster homolog 2 (SPNS2), where it binds to five transmembrane G protein-coupled receptors to mediate its oncogenic functions (S1PR1-S1PR5). MicroRNAs (miRNAs) are small non-coding RNAs, 21–25 nucleotides in length, that play numerous crucial roles in cancer, such as tumor initiation, progression, apoptosis, metastasis, and angiogenesis via binding to the 3′‐untranslated region (3′‐UTR) of the target mRNA. There is growing evidence that various miRNAs modulate tumorigenesis by regulating the expression of SphKs, and S1P receptors. We have reviewed various roles of miRNAs, SphKs, S1P, and S1P receptors (S1PRs) in malignancies and how notable miRNAs like miR-101, miR-125b, miR-128, and miR-506, miR-1246, miR-21, miR-126, miR499a, miR20a-5p, miR-140-5p, miR-224, miR-137, miR-183-5p, miR-194, miR181b, miR136, and miR-675-3p, modulate S1P signaling. These tumorigenesis modulating miRNAs are involved in different cancers including breast, gastric, hepatocellular carcinoma, prostate, colorectal, cervical, ovarian, and lung cancer via cell proliferation, invasion, angiogenesis, apoptosis, metastasis, immune evasion, chemoresistance, and chemosensitivity. Therefore, understanding the interaction of SphKs, S1P, and S1P receptors with miRNAs in human malignancies will lead to better insights for miRNA-based cancer therapy.
- 20 September 2021
- Published by Springer Nature in Discover Oncology
- Vol. 12 (1) , 1-19
Open AccessInteraction of microRNAs with sphingosine kinases, sphingosine-1 phosphate, and sphingosine-1 phosphate receptors in cancer
Sphingosine-1-phosphate (S1P), a pleiotropic lipid mediator, participates in various cellular processes during tumorigenesis, including cell proliferation, survival, drug resistance, metastasis, and angiogenesis. S1P is formed by two sphingosine kinases (SphKs), SphK1 and SphK2. The intracellularly produced S1P is delivered to the extracellular space by ATP-binding cassette (ABC) transporters and spinster homolog 2 (SPNS2), where it binds to five transmembrane G protein-coupled receptors to mediate its oncogenic functions (S1PR1-S1PR5). MicroRNAs (miRNAs) are small non-coding RNAs, 21–25 nucleotides in length, that play numerous crucial roles in cancer, such as tumor initiation, progression, apoptosis, metastasis, and angiogenesis via binding to the 3′‐untranslated region (3′‐UTR) of the target mRNA. There is growing evidence that various miRNAs modulate tumorigenesis by regulating the expression of SphKs, and S1P receptors. We have reviewed various roles of miRNAs, SphKs, S1P, and S1P receptors (S1PRs) in malignancies and how notable miRNAs like miR-101, miR-125b, miR-128, and miR-506, miR-1246, miR-21, miR-126, miR499a, miR20a-5p, miR-140-5p, miR-224, miR-137, miR-183-5p, miR-194, miR181b, miR136, and miR-675-3p, modulate S1P signaling. These tumorigenesis modulating miRNAs are involved in different cancers including breast, gastric, hepatocellular carcinoma, prostate, colorectal, cervical, ovarian, and lung cancer via cell proliferation, invasion, angiogenesis, apoptosis, metastasis, immune evasion, chemoresistance, and chemosensitivity. Therefore, understanding the interaction of SphKs, S1P, and S1P receptors with miRNAs in human malignancies will lead to better insights for miRNA-based cancer therapy.